Elucidating the exact pharmacological mechanism of motion (MOA) of Normally happening compounds is often hard. While Tarselli et al. (60) developed the very first de novo artificial pathway to conolidine and showcased that this The natural way transpiring compound properly suppresses responses to the two chemically induced and inflammation-derived